Skyrizi is an effective treatment option for plaque psoriasis, Crohn’s disease, ulcerative colitis, and psoriatic arthritis. Success rates may vary depending on the condition being treated and ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

In its latest announcement, AbbVie said Skyrizi had beaten placebo at improving psoriatic arthritis outcomes patients in two phase 3 trials in psoriatic arthritis, as well as hitting important ...

Psoriatic arthritis treatments can vary depending on ... Other medications, such as Cosentyx, Taltz, Simponi, Skyrizi, and Stelara, require less frequent injections after initial doses.